Abbott Laboratories PT Raised to $40.00 at Barclays (ABT)
Equities researchers at Barclays raised their price objective on shares of Abbott Laboratories (NYSE:ABT) from $38.00 to $40.00 in a research report issued on Thursday, Stock Ratings Network reports. The firm currently has an “equal weight” rating on the stock. Barclays’ price objective would indicate a potential upside of 2.04% from the company’s current price.
ABT has been the subject of a number of other recent research reports. Analysts at Morgan Stanley upgraded shares of Abbott Laboratories from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday. They now have a $45.00 price target on the stock. Separately, analysts at Deutsche Bank raised their price target on shares of Abbott Laboratories from $37.00 to $39.00 in a research note to investors on Monday, December 16th. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Abbott Laboratories in a research note to investors on Friday, November 29th. They now have a $40.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $39.14.
Shares of Abbott Laboratories (NYSE:ABT) traded up 0.18% on Thursday, hitting $39.27. The stock had a trading volume of 4,996,794 shares. Abbott Laboratories has a 52-week low of $32.55 and a 52-week high of $39.69. The stock’s 50-day moving average is $37.86 and its 200-day moving average is $36.04. The company has a market cap of $60.719 billion and a P/E ratio of 20.49.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 16th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.03. The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.46 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. Analysts expect that Abbott Laboratories will post $2.01 EPS for the current fiscal year.
Abbott Laboratories (NYSE:ABT), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.